You're Taking Medications as Prescribed, Yet Having Severe Reactions. Here's the Biological Reason.

CYP2D6 is your liver’s most versatile drug-processing enzyme. It’s responsible for breaking down antidepressants, opioids, beta-blockers, codeine, and dozens of other common medications. Without functional CYP2D6, these drugs accumulate in your system instead of being cleared.

Variants like *2, *4, *10, and *17 reduce or eliminate enzyme activity. Poor metabolizers, roughly 7 to 10% of people with European ancestry, carry two nonfunctional copies. When they take a standard dose of an antidepressant or opioid, the drug builds up to toxic levels in their blood because their liver can’t process it fast enough. They experience severe side effects at doses that work fine for everyone else.

You feel it as dizziness, nausea, tremors, confusion, or cardiac arrhythmias. You think you’re allergic. You’re not. Your liver is simply drowning in a drug it cannot metabolize.

CYP2C19 has an unusual job: it activates clopidogrel (Plavix), converting the drug into its active form inside your body. Without working CYP2C19, clopidogrel never becomes active. You could be taking it for heart protection after a stent, and it’s doing nothing.

Variants *2 and *3 reduce enzyme function; roughly 2 to 15% of people, depending on ethnic ancestry, are poor metabolizers. Poor metabolizers on clopidogrel receive zero antiplatelet protection despite taking the medication as prescribed. For someone with a recent stent, this is life-threatening. The *17 variant does the opposite: rapid metabolizers clear clopidogrel so fast they experience elevated bleeding risk.

You might notice unusual bruising, bleeding gums, or blood in your stool. Or you might notice nothing until you have a stent thrombosis. CYP2C19 also metabolizes many PPIs and antidepressants, so poor metabolizers on those drugs experience accumulation and side effects.

CYP2C9 metabolizes warfarin, the blood thinner used to prevent clots in atrial fibrillation and after certain surgeries. It also processes NSAIDs and statins. Variants *2 and *3 slow enzyme activity. Roughly 5 to 10% of Europeans carry at least one slow variant.

If you have a CYP2C9 poor metabolizer variant and your doctor prescribes standard-dose warfarin, the drug accumulates in your blood much faster than expected, dramatically raising your bleeding risk. You could experience nosebleeds, blood in your urine, or dangerous internal bleeding from a dose that’s considered safe for average metabolizers.

With NSAIDs, poor metabolizers experience heightened risk of GI bleeding and cardiovascular events because the drug lingers longer in your system. With statins, accumulation raises the risk of muscle pain and rhabdomyolysis. You feel it as unexpected bruising, prolonged bleeding from cuts, or severe muscle aches that don’t match your activity level.

VKORC1 encodes the enzyme that recycles vitamin K inside your cells. Warfarin works by blocking this enzyme, reducing clotting factors and thinning your blood. The -1639G>A variant changes how sensitive your VKORC1 is to warfarin’s blocking effect.

The A allele, present in roughly 40% of Europeans, means your VKORC1 is naturally less active. Your cells recycle vitamin K more slowly, so warfarin has a much stronger effect on you than it would on someone with the G allele. You need significantly lower doses to achieve the same anticoagulation effect as an average metabolizer.

You experience this as bleeding that seems disproportionate to your warfarin dose. Small cuts bleed for too long. You develop bruises from minor bumps. Nosebleeds happen spontaneously. Your INR (International Normalized Ratio, the measure of blood thinness) climbs higher than expected, and your doctor keeps reducing your dose, confused by how sensitive you are.

TPMT metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine, immunosuppressants used for autoimmune conditions, transplant rejection prevention, and leukemia treatment. This is one of the oldest examples of pharmacogenomics in clinical practice, but many prescribers still ignore it.

TPMT poor metabolizers, roughly 0.3% of the population, are missing or have severely reduced enzyme function. When they take a standard dose of azathioprine or 6-MP, the drug and its toxic metabolites accumulate at levels that can destroy bone marrow cells, causing life-threatening anemia and infection. This isn’t a side effect. This is bone marrow suppression.

You experience severe fatigue, persistent infections, unexplained bruising, and bleeding. If the drug isn’t stopped immediately, it can be fatal. Intermediate metabolizers also have increased risk at standard doses. This is why TPMT testing before starting thiopurines is now standard of care in many hospitals, but still missed in outpatient settings.

SLCO1B1 encodes a transporter protein that pulls statins from your blood into liver cells, where they work and are metabolized. Without effective transport, statins linger in your bloodstream at higher concentrations than intended. The rs4149056 variant (C allele) reduces transport efficiency. Roughly 15% of the population carries at least one C allele.

If you have the C allele and take simvastatin or atorvastatin, statin levels in your blood rise much higher than expected at standard doses, dramatically increasing your risk of muscle pain, weakness, and rhabdomyolysis. You feel it as inexplicable muscle soreness that comes on after starting the drug, or after a dose increase.

Many people blame the statin itself and stop taking it, thinking they’re statin-intolerant. In reality, they needed a lower dose or a different statin (pravastatin and rosuvastatin are less dependent on SLCO1B1 transport). Your doctor runs a creatinine kinase test, sees it’s mildly elevated, and tells you you’re fine. But the damage is happening at the cellular level.